Differential co-expression between α-synuclein and IFN-γ signaling genes across development and in parkinson's disease

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Liscovitch, Noa ^a   French, Leon ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b ROTMAN RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GAMMA INTERFERON; PROTEIN INHIBITOR OF ACTIVATED STAT; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ADULT; AGE; ARTICLE; CELL ACTIVATION; CLAUSTRUM; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; GENETIC CORRELATION; HIPPOCAMPAL CA2 REGION; HPRT1 GENE; HUMAN; HUMAN TISSUE; HYPOGLOSSAL NUCLEUS; IFN GAMMA GENE; IMMUNOMODULATION; INSULA; MAJOR CLINICAL STUDY; MALE; METENCEPHALON; MICROGLIA; MIDDLE AGED; MORF4L2 GENE; NAP1L2 GENE; NERVE DEGENERATION; PARKINSON DISEASE; PCMT1 GENE; PIAS1 GENE; SIGNAL TRANSDUCTION; SNCA GENE; SOCS1 GENE; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA; SYNAPTIC TRANSMISSION; TELENCEPHALON; TEMPORAL LOBE; TRIGEMINAL NUCLEUS; UBE2E2 GENE; YOUNG ADULT; ZC3H15 GENE; BRAIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SUBSTANTIA NIGRA;

ANIMALIA;

AGE FACTORS; ALPHA-SYNUCLEIN; BRAIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; INTERFERON-GAMMA; PARKINSON DISEASE; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

EID: 84918587945     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115029     Document Type: Article

References (51)

1. Klein C, Westenberger A (2012) Genetics of Parkinson's disease. Cold Spring Harb Perspect Med 2: A008888. doi:10.1101/cshperspect.a008888.
2. Keller MF, Saad M, Bras J, Bettella F, Nicolaou N, et al. (2012) Using genome-wide complex trait analysis to quantify missing heritability'' in Parkinson's disease. Hum Mol Genet 21: 4996-5009. doi:10.1093/hmg/dds335.
3. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047. doi:10.1126/science.276.5321.2045.
4. OMIM (2014) Online Mendelian Inheritance in Man, OMIMH. Johns Hopkins University, Baltimore, MD. MIM Number: 163890: 2/3/2014. World Wide Web URL: Http://omim.org/.
5. Chen J, Mills JD, Halliday GM, Janitz M (2014) The role of transcriptional control in multiple system atrophy. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2014.08.015.
6. Marques O, Outeiro TF (2012) Alpha-synuclein: From secretion to dysfunction and death. Cell Death Dis 3: E350. doi:10.1038/cddis.2012.94.
7. Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, et al. (2012) An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 489: 391-399. Available: Http://www.ncbi.nlm.nih.gov/pubmed/22996553. Accessed 14 July 2014.
8. Miller JA, Ding S-L, Sunkin SM, Smith KA, Ng L, et al. (2014) Transcriptional landscape of the prenatal human brain. Nature 508: 199-206. Available: Http://www.ncbi.nlm.nih.gov/pubmed/24695229. Accessed 10 July 2014.
9. BrainSpan (2012) Website: -2012 Allen Institute for Brain Science. BrainSpan Atlas of the Developing Human Brain [Internet]. Available from: Http://brainspan.org/.
10. Zhang Y, James M, Middleton F, Davis RL (2005) Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am J Med Genet B Neuropsychiatr Genet 137B: 5-16. doi:10.1002/ajmg.b.30195.
11. Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RKB, et al. (2006) Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics 7: 1-11. doi:10.1007/s10048-005-0020-2.
12. Lesnick TG, Papapetropoulos S, Mash DC, Ffrench-Mullen J, Shehadeh L, et al. (2007) A genomic pathway approach to a complex disease: Axon guidance and Parkinson disease. PLoS Genet 3: 0984-0995. doi:10.1371/journal.pgen.0030098.
13. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, et al. (2010) PGC-1a, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2: 52ra73. doi:10.1126/scitranslmed.3001059.
14. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, et al. (2007) Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci 104: 955-960. doi:10.1073/pnas.0610204104.
15. Zoubarev A, Hamer KM, Keshav KD, McCarthy EL, Santos JRC, et al. (2012) Gemma: A resource for the reuse, sharing and meta-analysis of expression profiling data. Bioinformatics 28: 2272-2273. doi:10.1093/bioinformatics/bts430.
16. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z (2009) GOrilla: A tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 10: 48. doi:10.1186/1471-2105-10-48.
17. Kalaitzakis ME, Pearce RKB, Gentleman SM (2009) Clinical correlates of pathology in the claustrum in Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 461: 12-15. doi:10.1016/j.neulet.2009.05.083.
18. Christopher L, Koshimori Y, Lang AE, Criaud M, Strafella AP (2014) Uncovering the role of the insula in non-motor symptoms of Parkinson's disease. Brain 137: 2143-2154. Available: Http://www.ncbi.nlm. nih.gov/pubmed/24736308. Accessed 17 September 2014.
19. Oliver S (2000) Guilt-by-association goes global. Nature 403: 601-603. doi:10.1038/35001165.
20. Mart?n ED, González-Garc?a C, Milán M, Farin? as I, Cen?a V (2004) Stressor-related impairment of synaptic transmission in hippocampal slices from alpha-synuclein knockout mice. Eur J Neurosci 20: 3085-3091. doi:10.1111/j.1460-9568.2004.03801.x.
21. Chakrabarty P, Ceballos-Diaz C, Lin W-L, Beccard A, Jansen-West K, et al. (2011) Interferon-c induces progressive nigrostriatal degeneration and basal ganglia calcification. Nat Neurosci 14: 694-696. doi:10.1038/nn.2829.
22. Kim J-H, Jou I, Joe E-H (2014) Suppression of miR-155 Expression in IFN-c-Treated Astrocytes and Microglia by DJ-1: A Possible Mechanism for Maintaining SOCS1 Expression. Exp Neurobiol 23: 148-154. Available: Http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid54065828&tool5pmcentrez&rendertype5abstract. Accessed 17 September 2014.
23. Baumeister AA, Frye GD (1985) The biochemical basis of the behavioral disorder in the Lesch-Nyhan syndrome. Neurosci Biobehav Rev 9: 169-178. doi:10.1016/0149-7634(85)90043-0.
24. Jinnah HA, Ceballos-Picot I, Torres RJ, Visser JE, Schretlen DJ, et al. (2010) Attenuated variants of Lesch-Nyhan disease. Brain 133: 671-689. doi:10.1093/brain/awq013.
25. Ouazia D, Levros LC, Rassart É , Desrosiers RR (2014) Dopamine down-regulation of protein Lisoaspartyl methyltransferase is dependent on reactive oxygen species in SH-SY5Y cells. Neuroscience 267: 263-276. doi:10.1016/j.neuroscience.2014.03.001.
26. Ramsey CP, Giasson BI (2010) Identification and characterization of a novel endogenous murine parkin mutation. J Neurochem 113: 402-417. doi:10.1111/j.1471-4159.2010.06605.x.
27. Pankratz N, Beecham GW, Destefano AL, Dawson TM, Doheny KF, et al. (2012) Meta-analysis of Parkinson's Disease: Identification of a novel locus, RIT2. Ann Neurol 71: 370-384. doi:10.1002/ana.22687.
28. Nalls M, Pankratz N, Lill CM, Do CB, Hernandez DG, et al. (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 056: 1-7. doi:10.1038/ng.3043.
29. De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, et al. (2014) Alzheimer's disease: Early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci 17: 1156-1163. Available: Http://dx.doi.org/10.1038/nn.3786. Accessed 18 August 2014.
30. Lunnon K, Smith R, Hannon E, De Jager PL, Srivastava G, et al. (2014) Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nat Neurosci 17: 1164-1170. Available: Http://www.ncbi.nlm.nih.gov/pubmed/25129077. Accessed 18 August 2014.
31. Greene JG (2012) Current status and future directions of gene expression profiling in Parkinson's disease. Neurobiol Dis 45: 76-82. doi:10.1016/j.nbd.2010.10.022.
32. Sutherland GT, Matigian NA, Chalk AM, Anderson MJ, Silburn PA, et al. (2009) A cross-study transcriptional analysis of Parkinson's disease. PLoS One 4. doi:10.1371/journal.pone.0004955.
33. Attia M, Rachez C, De Pauw A, Avner P, Rogner UC (2007) Nap1l2 promotes histone acetylation activity during neuronal differentiation. Mol Cell Biol 27: 6093-6102. Available: Http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid51952155&tool5pmcentrez&rendertype5abstract. Accessed 1 November 2014.
34. Cai Y, Jin J, Tomomori-Sato C, Sato S, Sorokina I, et al. (2003) Identification of new subunits of the multiprotein mammalian TRRAP/TIP60-containing histone acetyltransferase complex. J Biol Chem 278: 42733-42736. Available: Http://www.ncbi.nlm.nih.gov/pubmed/12963728. Accessed 1 November 2014.
35. Kontopoulos E, Parvin JD, Feany MB (2006) Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15: 3012-3023. Available: Http://www.ncbi.nlm. nih.gov/pubmed/16959795. Accessed 1 November 2014.
36. Kannarkat GT, Boss JM, Tansey MG (2013) The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis 3: 493-514. Available: Http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid54102262&tool5pmcentrez&rendertype5abstract. Accessed 13 October 2014.
37. Mount MP, Lira A, Grimes D, Smith PD, Faucher S, et al. (2007) Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 27: 3328-3337. Available: Http://www.ncbi.nlm.nih.gov/pubmed/17376993. Accessed 17 September 2014.
38. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, et al. (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 42: 781-785. doi:10.1038/ng.642.
39. Ahmed I, Tamouza R, Delord M, Krishnamoorthy R, Tzourio C, et al. (2012) Association between Parkinson's disease and the HLA-DRB1 locus. Mov Disord 27: 1104-1110. doi:10.1002/mds.25035.
40. Gardet A, Benita Y, Li C, Sands BE, Ballester I, et al. (2010) LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol 185: 5577-5585. Available: Http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid53156100&tool5pmcentrez&rendertype5abstract. Accessed 17 September 2014.
41. Powers KM, Kay DM, Factor S, Zabetian CP, Higgins DS, et al. (2008) Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord 23: 88-95. doi:10.1002/mds.21782.
42. Tebow G, Sherrill DL, Lohman IC, Stern DA, Wright AL, et al. (2008) Effects of parental smoking on interferon gamma production in children. Pediatrics 121: E1563-e1569. doi:10.1542/peds.2007-2795.
43. Ritter M, Hohenberger K, Alter P, Herzum M, Tebbe J, et al. (2005) Caffeine inhibits cytokine expression in lymphocytes. Cytokine 30: 177-181. Available: Http://www.ncbi.nlm.nih.gov/pubmed/15863391. Accessed 17 September 2014.
44. Gagne JJ, Power MC (2010) Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis. Neurology 74: 995-1002. doi:10.1212/WNL.0b013e3181d5a4a3.
45. Dinh K, Poindexter BJ, Barnes JL, Schiess MC, Bick RJ (2009) Fluorescence microscopy and 3D image reconstruction of cytokine initiated disruption of the Parkinson disease associated proteins alphasynuclein, tau and ubiquitin in cultured glial cells. Cytokine 45: 179-183. Available: Http://www.ncbi.nlm. nih.gov/pubmed/19157893. Accessed 1 November 2014.
46. Kim S, Seo J-H, Suh Y-H (2004) Alpha-synuclein, Parkinson's disease, and Alzheimer's disease. Parkinsonism Relat Disord 10 Suppl 1: S9-13. Available: Http://www.sciencedirect.com/science/article/pii/S1353802004000033. Accessed 10 October 2014.
47. Markopoulou K, Biernacka JM, Armasu SM, Anderson KJ, Ahlskog JE, et al. (2014) Does asynuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease? Parkinsonism Relat Disord 20: 584-9; discussion 584. Available: Http://www.ncbi.nlm.nih.gov/pubmed/24656894. Accessed 17 September 2014.
48. Harms AS, Cao S, Rowse AL, Thome AD, Li X, et al. (2013) MHCII is required for a-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci 33: 9592-9600. Available: Http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid53903980&tool5pmcentrez&rendertype5abstract. Accessed 17 September 2014.
49. Barcia C, Ros CM, Annese V, Gomez A, Ros-Bernal F, et al. (2011) IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis Dis 2: E142. doi:10.1038/cddis.2011.17.
50. Austin SA, Rojanathammanee L, Golovko MY, Murphy EJ, Combs CK (2011) Lack of alphasynuclein modulates microglial phenotype in vitro. Neurochem Res 36: 994-1004. Available: Http://www.ncbi.nlm.nih.gov/pubmed/21384098. Accessed 14 October 2014.
51. Austin SA, Floden AM, Murphy EJ, Combs CK (2006) Alpha-synuclein expression modulates microglial activation phenotype. J Neurosci 26: 10558-10563. Available: Http://www.ncbi.nlm.nih.gov/pubmed/17035541. Accessed 14 October 2014.